The articular cartilage in the knee has a limited capacity to repair itself. Procedures can treat localized defects and improve function in selected patients, but this does not mean fully rebuilding the original cartilage in any knee. There is also no basis for promising that an injection will make a joint with osteoarthritis normal again.[1,5]

The answer, then, is not an absolute yes or no. We need to know which lesion is present, what tissue the treatment aims to produce, and what it has demonstrated: less pain, better movement, or structural repair. Confusing these outcomes is a major source of unmet expectations.

Repair does not necessarily reproduce the original tissue

The surface covering the ends of bones consists mainly of hyaline cartilage, specialized to allow low-friction movement. Its healing capacity is limited. When a treatment promotes filling of a defect, the resulting tissue may differ from what was there before.[1]

Fibrocartilage is one example: it can contribute to repair, but its organization and mechanical strength differ from those of hyaline cartilage. This does not make every repair useless. It means that filling an area, improving symptoms, and restoring the same original structure are distinct goals. A responsible explanation needs to say which of these is plausible in that particular case.[1]

Focal lesions, chondromalacia, and osteoarthritis are not synonyms

A focal lesion is a localized defect that may occur after trauma and coexist with relatively preserved areas. Chondromalacia describes softening and deterioration of cartilage, often on the back of the kneecap; the term alone does not establish the cause of pain or the need for surgery. Patellofemoral pain can exist without this cartilage damage.[1,2]

In osteoarthritis, the problem involves the joint more broadly. The strategy for an isolated defect should not automatically be transferred to a knee with widespread cartilage loss. Nor does the word chondromalacia in a report mean that the person will inevitably develop disabling osteoarthritis. Before discussing regeneration, it is necessary to clarify which of these scenarios is present.[1,2,5]

Imaging should help explain the problem, not decide on its own

MRI helps assess the location, extent, and depth of the defect, as well as the bone just beneath the cartilage. But the decision also depends on the physical examination, symptoms, and what the person needs to do. An imaging abnormality does not automatically require an intervention to fill it.[1,2]

When assessing suitability for restoration, leg alignment, ligament stability, and meniscal function matter. If the area remains overloaded or the knee unstable, treating the defect alone may be insufficient. The question is not just how much cartilage is missing, but the environment in which that tissue will have to function.[1]

Improvement is possible without demonstrating cartilage growth

Well-conducted rehabilitation can improve strength, movement control, and tolerance for activities, particularly in people with patellofemoral pain. Temporarily adjusting loads and restoring physical capacity is not giving up on treatment because a regenerative technique is unavailable. It means working on factors that influence how the knee functions.[2]

Less pain does not prove that cartilage has grown; a persistent MRI abnormality does not mean treatment has failed either. The outcome should be assessed against the agreed goal. A person may return to important tasks without the imaging appearance becoming identical to that of a knee that has never been injured.[2,3]

What cartilage restoration surgery can offer

In microfracture, small perforations in the bone beneath the defect stimulate a repair response, usually involving fibrocartilage. The technique has a role in selected lesions, but should not be presented as a simple solution for every defect size or level of activity demand. Its indication needs to consider durability and possible consequences for future procedures.[1]

Osteochondral transplantation transfers hyaline cartilage together with its supporting bone, from the patient or a donor, depending on the case. Chondrocyte implantation uses cartilage cells to treat specific defects. These are different strategies, with limitations involving the donor area, integration, complexity, and availability; none allows indiscriminate treatment of diffuse osteoarthritis.[1]

In the SUMMIT study, matrix-applied chondrocyte implantation produced better pain and function outcomes than microfracture at five years in selected adults with symptomatic defects of at least three square centimeters. MRI assessment, however, showed no significant difference between the groups in structural repair. This is an important clinical result, not proof of a biologically new knee.[3]

PRP and cell-based treatments: ask what has been demonstrated

Platelet-rich plasma (PRP) is prepared from blood and is not the same as a stem cell injection. For osteoarthritis, some studies and consensus statements support symptomatic benefit in selected patients. However, the RESTORE trial did not demonstrate an advantage of the studied protocol over placebo for pain or cartilage volume at 12 months. Symptom-related results do not justify promises of structural regeneration.[4,7]

Bone marrow concentrate, fat-derived preparations, and cultured cells are not interchangeable products either. Bone marrow concentrate does not mean purified stem cells. For advanced osteoarthritis, AAHKS does not recommend routine use of PRP, bone marrow concentrate, or mesenchymal cells; this should not be extrapolated into an assessment of all surgery for focal lesions.[5]

In Brazil, CFM Resolution 2.464/2026 regulates PRP as an adjunct for specific conditions, including knee osteoarthritis, without authorizing promises of guaranteed regeneration. This rule is not a blanket authorization for cell-based treatments. Before accepting a proposal, ask which product will be used, for which diagnosis, with what evidence, and with what risks.[6]

Rehabilitation and expectations are part of the indication

Cartilage procedures may require protected weight-bearing, careful progression, and months of recovery. The protocol depends on the location, technique, and associated corrective procedures. Knowing whether surgery is technically possible is not enough: it is necessary to assess whether the person can follow that pathway. Return to sport should not be promised on the basis of a fixed date or the appearance of an MRI alone.[1]

Frequently asked questions

Does chondromalacia mean I need surgery?

No. The term describes a cartilage abnormality and needs to be related to symptoms and examination findings. In many patellofemoral conditions, rehabilitation and activity adjustments are central to care; a report alone does not indicate surgery.[2]

If MRI shows that the defect has filled, is the cartilage back to normal?

Not necessarily. Filling alone does not establish the tissue’s composition, integration, or durability. Pain, function, and progress also need assessment; structural repair and clinical recovery are related but different dimensions.[1,3]

Conclusion

Preserving a knee requires more precision than a promise of regeneration. Real progress lies in better selection of who may benefit from each strategy and clear explanation of its limitations. Before asking whether a technique makes cartilage grow, it is worth asking whether it treats the right problem and offers an improvement that is meaningful for that person.